Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment
John T. Isaacs(Brady (Norway)), Tomas Leanderson(Lund University), W. Nathaniel Brennen(Johns Hopkins University), Michel D. Wissing(Johns Hopkins University), Susan L. Dalrymple(Johns Hopkins University), Jun Luo(Johns Hopkins University), Sushant K. Kachhap(Johns Hopkins University), Anders Björk(Johns Hopkins University), Hans J. Hammers(Southwestern Medical Center), Li Xing(University of California, Irvine), Per Björk(Active Biotech (Sweden)), Stephanie Gerber(Johns Hopkins University), Lizamma Antony(Johns Hopkins University), Anders Olsson(Linköping University)
Cited by 113
Related Papers
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
|The Lancet|2014|750
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19
|Journal of Allergy and Clinical Immunology|2020|694